Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESSENTIAL: Nangibotide in COVID-19
NCT04429334Phase 2Completed
- Sponsor
- Inotrem
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of nangibotide in coronavirus disease 2019 (COVID-19), sponsored by Inotrem. Started Sep 2020; status: completed.
02
Drugs
nangibotide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04429334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429334.